The Croda International-backed biopharmaceutical developer has cloesd a $13.2m round to boost its overall funding to about $25m.
SiSaf, a UK-based drug delivery technology developer backed by specialty chemicals producer Croda International, has raised $13.2m in its series B round.
The round was led by venture capital firm Vickers Venture Partners with an investment matched by the UK government’s Future Fund.
Sisaf has developed bio-courier technology that facilitates the safe delivery of RNA therapeutics used to treat genetic conditions. It forms the basis of a pipeline of drug candidates that include potential treatments for genetic bone and eye…
